Anti-Activin vs GLP-1 Agonist — Metabolic Deal Terms Comparison
Market Analysis
In metabolic, Anti-Activin and GLP-1 Agonist represent two of the most actively transacted modalities. At Phase 2, Anti-Activin deals carry a median total deal value of $4.9B with $1.0B upfront, compared to $4.5B total value and $935M upfront for GLP-1 Agonist. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.
Milestone structures diverge between the two modalities. Anti-Activin development milestones average $695M versus $647M for GLP-1 Agonist. Commercial milestones are $2.3B for Anti-Activin and $2.2B for GLP-1 Agonist. Royalty rates range from 16.5%-30% for Anti-Activin and 16.1%-29.5% for GLP-1 Agonist.
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
How do Anti-Activin and GLP-1 Agonist deal terms compare in metabolic?
Which modality commands higher royalty rates: Anti-Activin or GLP-1 Agonist?
How do milestone structures differ between Anti-Activin and GLP-1 Agonist?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.